Takeda Pharma agreed to buy London-listed Shire for £45.3 billion (US$61.50 billion) on Tuesday, May 8, after the Japanese company raised the amount of cash in its offer to US$30.33 cash and 0.839 shares of Takeda per share of Shire to secure a recommendation, reported The Wall Street Journal.
The deal will be the largest overseas acquisition by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top ranks of global drugmakers.
“Together, we will be a leader in providing targeted treatments in gastroenterology, neuroscience, oncology, rare diseases and plasma-derived therapies,” he said.
The tie-up will also be one of the largest ever in the pharmaceuticals sector, reported WSJ.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
South Dakota Reaches Settlement With NCAA Ahead of Antitrust Payout Approval
Apr 23, 2025 by
CPI
Judge Allows Yelp’s Antitrust Lawsuit Against Google to Proceed
Apr 23, 2025 by
CPI
Meta Lawyers Try to Undercut Instagram Co-Founder’s Damaging Testimony
Apr 23, 2025 by
CPI
Tyson Foods, Others Settle Pork Price-Fixing Suit for $64 Million
Apr 23, 2025 by
CPI
NJ Sues RealPage, Landlords Over Rent Collusion
Apr 23, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece